The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role?
The Nrf2 Activator (DMF) and Covid-19: Is there a Possible Role?
复制标题
DOI：
10.5455/medarh.2020.74.134-138
复制
发表时间：
2020-04-01
期刊：
影响因子：
--
通讯作者：
Hadi, Najah R
中科院分区：
文献类型：
--
作者：
Hassan, Saif M;Jawad, Mahmood J;Hadi, Najah R
简介：COVID-19 是一种新的病毒性疾病，会影响肺部和呼吸道，造成致命后果，导致患者死亡。 ACE2 受体在肺、肾、小肠、心脏等身体组织中受到不同程度的广泛干扰，并被认为是 nCOVID-19 病毒的目标。病毒的 S 蛋白与 ACE2 受体结合，导致内源性抗病毒介质下调，NF-κB 通路、ROS 和促凋亡蛋白上调。 Nrf2 是一种在抗氧化酶的生成中发挥作用的转录因子。目的：描述和建立 Nrf2 激活剂在治疗 COVID-19 阳性患者中的作用。方法：我们使用已发表论文的分析方法，描述了与全球抗击 COVID-19 感染的药理学问题和方面有关的 COVID-19 研究，以及在 nCOVID-19 临床试验中使用 DMF（Nrf2 激活剂）如何产生积极影响结果：我们发现Nrf2激活剂是一种重要的药物，通过诱导SPLI基因表达抑制病毒进入，抑制TRMPSS2，上调ACE2与病毒竞争结合位点，诱导RIG-1和INF等抗病毒介质的基因表达，诱导抗氧化酶，并具有抑制病毒发病的作用，从而减少病毒发病。 NF-kappaB通路，抑制凋亡蛋白和TLRs基因表达。结论：我们得出结论，在nCOVID-19阳性患者的临床试验中使用DMF（Nrf2激活剂）可以减少肺泡细胞损伤。
INTRODUCTION: COVID-19 is a new viral illness that can affect the lungs and airways with lethal consequences leading to the death of the patients. The ACE2 receptors were widely disturbed among body tissues such as lung, kidney, small intestine, heart, and others in different percent and considered a target for the nCOVID-19 virus. S-protein of the virus was binding to ACE2 receptors caused downregulation of endogenous anti-viral mediators, upregulation of NF-kappaB pathway, ROS and pro-apoptotic protein. Nrf2 was a transcription factor that's play a role in generation of anti-oxidant enzymes.AIM: To describe and establish role of Nrf2 activators for treatment COVID-19 positive patients.METHODS: We used method of analysis of the published papers with described studies about COVID-19 connected with pharmacological issues and aspects which are included in global fighting against COVID-19 infection, and how using DMF (Nrf2 activator) in clinical trial for nCOVID-19 produce positive effects in patients for reduce lung alveolar cells damage.RESULTS: we are found that Nrf2 activators an important medication that's have a role in reduce viral pathogenesis via inhibit virus entry through induce SPLI gene expression as well as inhibit TRMPSS2, upregulation of ACE2 that's make a competition with the virus on binding site, induce gene expression of anti-viral mediators such as RIG-1 and INFs, induce anti-oxidant enzymes, also they have a role in inhibit NF-kappaB pathway, inhibit both apoptosis proteins and gene expression of TLRs.CONCLUSION: We are concluded that use DMF (Nrf2 activator) in clinical trial for nCOVID-19 positive patients to reduce lung alveolar cells damage.